Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection PEX168 Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pegloxenatide (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 21 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 21 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.